
Senseonics starts first human trial of Freedom, a transmitter-free CGM system aiming for 2028 launch
Senseonics Holdings has begun the first human clinical trial of Freedom, a next-generation continuous glucose monitoring (CGM) system designed without an external on-body transmitter. This implantable device communicates directly with mobile devices ...





